Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are ...

Karolinska Development (STO:KDEV) has stopped investing in three of its portfolio biotechs and fully written off its outlay in the businesses to date. The decisions contributed to the valuation of the ...

This article is intended for those of you who are at the beginning of your investing journey and want to better understand how you can grow your money by investing in Karolinska Development AB (publ) ...

Karolinska Development (STO:KDEV) has slashed the value of its portfolio after adopting a new way of tallying up what its early-stage biotech investments are worth. The new accounting model and the ...

Karolinska Development [KDEV], developer of life science innovations that meet tomorrow's medical need, will visit the NASDAQ MarketSite in Times Square. In honor of the occasion, Torbjörn Bjerke, CEO ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement from Karolinska ...

Karolinska Development AB is getting an SEK220 million ($33.7 million) cash injection from Rosetta Capital Ltd. for 13 of the 25 companies in its portfolio. The new money will go a long way toward ...

New firm will include existing portfolio company Akinion and four to five new project businesses. Swedish life science investor and incubator organization Karolinska Development has established a new ...

If the original Linux-based FoxBox SMS didn't boast quite the capabilities you were looking for, then perhaps KDev's upgraded FoxBox MMS will be more to your liking. Like the original FoxBox, it'll ...

As of 4:50:23 pm GMT+1. Market open.

As of 1:06:04 pm GMT+1. Market open.

Karolinska Development AB ( (SE:KDEV)) has issued an announcement. Karolinska Development’s portfolio company, SVF Vaccines, has presented promising preclinical data on its immunotherapy, SVF-001, ...